Hester Biosciences Secures License for Avian Influenza Vaccine
Filing Summary
Hester Biosciences Limited has obtained a manufacturing license from the Food & Drugs Control Administration for the production and marketing of the Low Pathogenic Avian Influenza Vaccine, specifically the Inactivated H9N2 strain, for poultry. This development marks a regulatory milestone for the company in its poultry healthcare portfolio. The vaccine technology was acquired from ICAR-NIHSAD through Agrinnovate India. The H9N2 strain is known for causing economic losses in poultry due to its impact on egg production and broiler performance.
On 24 January 2026, Hester Biosciences Limited announced that it has received a manufacturing license from the Food & Drugs Control Administration. This license permits the company to manufacture and market the Low Pathogenic Avian Influenza Vaccine, specifically the Inactivated H9N2 strain, for poultry.
The H9N2 strain of avian influenza presents a persistent challenge in poultry flocks. It is associated with year-round comorbidity, leading to significant economic losses. The strain can cause an irreversible drop in egg production in layers and performance loss in broilers. Additionally, it can result in high mortality rates when combined with other infections.
This regulatory approval represents a significant milestone for Hester Biosciences in advancing its prevention-led poultry healthcare portfolio. The vaccine was developed using technology acquired from ICAR-NIHSAD via Agrinnovate India.
Hester Biosciences Limited focuses on the development and manufacturing of animal vaccines and health products. The company prioritizes innovation in veterinary healthcare, aiming to address challenges in animal health and productivity through its diverse product offerings.